trial · primary record
Autologous B7-H3 CAR T
Recurrent Small Cell Lung Cancer
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2031-01-30 |
| Primary endpoint | Determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of autologous B7-H3 CAR T cells |
| Registry ID | NCT07509034 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:07.966Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07509034
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.